Proteomics International signs binding letter of intent with Sonic Healthcare USA to take PromarkerD into the US market

We are pleased to announce the signing of a binding and exclusive letter of intent (LOI) with Sonic Healthcare USA a division of Sonic Healthcare Limited (ASX: SHL). This is the prelude to entering into an exclusive licence for use of the Company’s PromarkerD test for diabetic kidney disease in the United States.

The LOI documents how Proteomics International and Sonic Healthcare USA will work together to achieve commercial sales of PromarkerD in the US in the coming months.

ASX Release


  • This field is for validation purposes and should be left unchanged.